Pfizer's Oncology Growth Story Ahead of Q2 Results

Markets are awaiting Pfizer's (NYSE: PFE) Q2 2025 earnings release, with a particular focus on the performance of its oncology segment. According to a report from Zacks, the oncology business is expected to show growth driven by key cancer drugs, biosimilars, and pipeline developments, potentially offsetting declines in older therapies.

Growth Drivers

Key oncology drugs such as Ibrance, Xtandi, and Inlyta are expected to continue generating strong revenues. Pfizer's biosimilars are also contributing to revenue growth, especially in emerging markets. Additionally, pipeline updates may yield new treatments that support long-term growth.

Challenges

On the other hand, Pfizer faces declining sales of some older drugs due to patent expirations and generic competition. However, growth in oncology is believed to offset this decline.

Context

This report comes ahead of Q2 results, which will be pivotal in assessing Pfizer's performance amid its strategic shift toward oncology. Notably, Pfizer recently acquired Seagen to strengthen its position in this field.

What This Means for Investors

While no buy or sell recommendation is made, the focus on oncology highlights Pfizer's commitment to innovation in cancer treatments. The segment's performance may be a key indicator of the company's ability to offset revenue declines from older products.